Browse studies

Find your next paid study

123 recruiting studies matching your filters

A Phase 2 Study of Fixed Duration Therapy With Pirtobrutinib and Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (POP)

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chro…

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator stu…

Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT06876662

Phase 1

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or re…

Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCL+23 more

Estimated

~$10 – $8,750

Long-term Follow-up Study of Patients Receiving CAR-T Cells

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wis…

Chronic Lymphocytic LeukemiaLymphomas Non-Hodgkin's B-CellLymphoma, Small Lymphocytic+6 more

Estimated

~$10 – $750

Medical College of WisconsinNCT03375619

Phase 1

A Phase 1/2, Open Label, Study of Roginolisib (IOA-244), an Orally Bioavailable, Selective PI3Kδ Inhibitor in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) in Combination With Venetoclax and Rituximab

This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants wi…

LeukemiaRelapsed LeukemiaChronic Lymphocytic Leukemia+2 more

Estimated

~$10 – $7,500

Jennifer R. Brown, MD, PhDNCT06644183

Observational

Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors

This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtroni…

Atrial FibrillationSupraventricular ArrhythmiaVentricular Arrhythmias and Cardiac Arrest+2 more

Estimated

~$10 – $7,500

Northwell HealthNCT05643235

Phase 1

A Phase Ib Study Evaluating the Safety and Efficacy of Tafasitamab, Acalabrutinib, and Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic l…

Chronic Lymphocytic Leukemia

Estimated

~$10 – $7,500

OHSU Knight Cancer InstituteNCT05943496

Phase 3

A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in comb…

Chronic Lymphocytic Leukemia

A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tole…

Non Hodgkin LymphomaRichter TransformationMultiple Myeloma+10 more

Estimated

~$10 – $8,750

Newave Pharmaceutical IncNCT04771572

Metabolic Profiling of Leukemic Cells Through Isotope Tracing in Patients With CLL

Metabolic reprogramming has been identified as a hallmark of cancer. Almost a century after Otto Warburg initially discovered increased glycolytic activity in …

Chronic Lymphocytic Leukemia

Estimated

~$10 – $750

University of Wisconsin, MadisonNCT04785989

Phase 2

Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell Transplant

This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) mat…

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+7 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT06059391

Phase 2

A Feasibility Study Following a Phase 2a Design to Demonstrate Successful Local Manufacture of Chimeric Antigen Receptor (CAR) T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell L…

B-Cell LymphomaB Acute Lymphoblastic LeukemiaDiffuse Large B Cell Lymphoma+6 more

Estimated

~$10 – $7,500

John ListerNCT05281809